The headline figure from the half-year update to the Swiss Venture Capital Report, published in July by startupticker.ch and the investor association SECA, is easy to misread. Swiss startups closed 123 financing rounds worth CHF 1.245 billion between January and June 2026, a drop of 15.5% on the same period of 2025. Read on its own, that sounds like a market cooling off.
Read against its comparison base, it sounds different. The first half of 2025 came in at CHF 1.47 billion, the third-highest half-year ever recorded, and the number of rounds barely moved, slipping from 124 to 123. That follows a full-year 2025 total of CHF 2.95 billion, nearly 24% above 2024, with early-stage investment hitting a record CHF 1.116 billion. In other words, 2026 opened with a step back from a recovery year, not a return to the funding winter of 2023 and 2024.
Hardware breaks its own record
The standout of the half-year was hardware. Swiss hardware startups raised CHF 324 million, more than 60% above the sector's previous six-month peak of just over CHF 200 million, set in the second half of 2021. The strength was not one lucky deal: four hardware companies appear among the ten largest rounds of the period.
The two largest hardware financings were each worth roughly CHF 177 to 178 million: Zug-based terralayr, which builds and operates grid-scale battery storage, and Kandou, an EPFL spinout designing energy-efficient connectivity chips for AI-era computing. Further down, SWISSto12 raised CHF 25.2 million to industrialize its HummingSat satellite platform, and Lausanne's PAVE Space closed an unusually large seed round for a vehicle that moves satellites between orbits. Chips, energy, and space: the pattern is research converting into fundable companies in exactly the fields where Swiss universities are strongest.
It also redrew the cantonal map. Vaud moved to the top of the table with CHF 330 million invested, a level comparable to the record years of 2021 and 2022, driven by three Vaud-based hardware companies in the top ten rounds. Zurich, by contrast, recorded its weakest half-year since 2018, held back by the absence of large biotech rounds and flat financing in software.
The headline fell, but the deal count held, seed rounds grew, and investors turned more confident. That is a recalibration, not a retreat.
Biotech cools while seed warms
Biotech, Switzerland's traditional heavyweight, raised only CHF 184 million, a fall of more than 70%, and the number of biotech rounds halved. Most of the headline decline sits right here. The report reads it as timing rather than weakness: strong companies used the exceptional 2025 to secure their capital, which left less pent-up demand for 2026.
The early end of the pipeline tells a more encouraging story. Seed investment rose 68.8% to CHF 156 million. The number of seed rounds was unchanged, so the whole increase came from larger cheques, pushing the median round to a record CHF 2.7 million. Early-stage investment fell 29.1% but still ranked as the second-highest first half of the past decade. Founders are still starting companies and still finding backers; investors are simply writing bigger cheques into the same number of rounds.
The late-stage gap, and who fills it
The weak link is further up the ladder. Late-stage investment fell 12.6%, and a longer view shows this is where Switzerland repeatedly falls short: late-stage amounts were larger in six of the past ten years. The Swiss Deep Tech Report 2026 quantifies the underlying structural issue: foreign investors supply 88% of Swiss late-stage funding in rounds of USD 100 million and above, with domestic capital contributing just 12%.
The practical reading is double-edged. Swiss-based companies clearly have access to deep international pools of growth capital, which matters for any foreign founder worried that a Swiss domicile might limit later fundraising. The flip side is that cap tables internationalize early, and the Swiss growth-stage layer remains thin enough that the report names it as the clearest obstacle to a sustained rise in total investment.
Investors are more confident than a year ago
The half-year update also surveys the investor community, and here the shift is clearer than in the deal data. Of the roughly 75 Swiss investors polled, 82% plan to invest more over the next twelve months, up from 72% a year earlier. Nine in ten expect more investment opportunities, and 78% expect more exit activity. On the supply side, 74% of managers still hold dry powder above 40% of their fund's original size, and eleven new funds launched in the half, against nine in the same period last year.
Pricing expectations moved with sentiment. A majority of respondents (53%) expect valuations to rise by up to 25% over the next year, and close to a quarter expect gains of 25% to 50%, compared with just 8% in the previous survey. Exits, which the report calls the most important prerequisite for a revival of the market, showed early signs of life: strategic investments by corporates such as ENGIE, Johnson & Johnson, and UBS doubled to 14, twice the count of both 2023 and 2024, and two sizeable exits stood out: Eli Lilly's purchase of LimmaTech Biologics, for up to CHF 613 million, and Amazon's acquisition of RIVR, a delivery-robot company spun out of an ETH Zurich lab.
AI, software, and what investors now underwrite
Switzerland has largely missed the very large AI financings that distort totals elsewhere, and its investors are cautious about them: about two thirds of respondents view current AI pricing with some degree of skepticism. A second concern is closer to home. Swiss ICT startups lean heavily on business software, and slightly more than half of investors see AI as a real threat of displacement to the software-as-a-service model.
The defenses they name are specific: vertical or domain specialization and regulatory positioning come first, followed by proprietary data and deep integration into customer workflows. The signal for founders is that raw AI capability is no longer what gets underwritten. Defensibility is.
What this means for a company evaluating Switzerland
For a foreign startup or SME weighing a Swiss base, three takeaways follow from the data. First, this is a selective market rather than a frothy one: the largest rounds are going to companies with real revenue, so a clear defensibility story and clean fundamentals matter more than momentum. Second, the seed stage is healthy and getting better funded, with a record median round, which helps a company establishing itself before its first major raise. Third, growth capital will most likely come from outside Switzerland, so corporate structure and cap table design are best planned with international investors in mind from day one rather than retrofitted at Series B.
None of this changes the underlying case for the country. It sharpens it: a compact, research-driven ecosystem producing world-class companies, now waiting on the growth capital to match.